BiotechTube

IBI112 + placebo /IBI112 + IBI112

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriasis

Conditions

Psoriasis

Trial Timeline

Feb 10, 2023 → Aug 1, 2024

NCT ID
NCT05645627

About IBI112 + placebo /IBI112 + IBI112

IBI112 + placebo /IBI112 + IBI112 is a phase 3 stage product being developed by Innovent Biologics for Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT05645627. Target conditions include Psoriasis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05645627Phase 3Completed

Competing Products

20 competing products in Psoriasis

See all competitors
ProductCompanyStageHype Score
Ixekizumab + PlaceboEli LillyPhase 2
52
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + PlaceboVentyx BiosciencesPhase 2
47
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo SubcutaneousEli LillyPhase 2
52
IxekizumabEli LillyPhase 3
77
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + PlaceboEli LillyPhase 3
77
Placebo + BaricitinibEli LillyPhase 2
52
CT-P43 + StelaraCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
CT-P55 + EU-approved CosentyxCelltrionPhase 3
77
AMG 139AstraZenecaPhase 1
33
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
85
alefaceptAstellas PharmaPhase 2
52
Tacrolimus CreamAstellas PharmaPhase 3
77
alefaceptAstellas PharmaPhase 3
77
peficitinib + PlaceboAstellas PharmaPhase 2
52
AlefaceptAstellas PharmaPhase 3
77
Amevive exposureAstellas PharmaPre-clinical
23
alefacept + placeboAstellas PharmaPhase 3
77
alefaceptAstellas PharmaApproved
85
ASKP1240 + PlaceboAstellas PharmaPhase 2
52

Other Products from Innovent Biologics

Taxane and Carboplatin + Short-term SintilimabApproved
84
Teprotumumab N01 + MethylprednisoloneApproved
84
IBI311Phase 3
76
Febuxostat + TigulixostatPhase 3
76
IBI301 plus CHOP + Rituximab plus CHOPPhase 3
76